TICKERNERD
Menu
PHATPHATHealthcare · Biotechnology

PHAT Stock Forecast: Phathom Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$8.98
+2.63% on the day

The 11 Wall Street analysts covering Phathom Pharmaceuticals, Inc. hold a median 12-month price target of $24 — +167.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$697.9M
Ticker Nerd rank
76 / 100
Median analyst target
$24
Analysts covering
11
Total return, dividends reinvested
1W
−24.9%
1M
−19.8%
YTD
−45.9%
1Y
+7.5%
From 52W high
−50.3%
From 52W low
+7.2%
$8
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHAT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phathom Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
76 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Quality
85
Value
83
Issuance
68
Accruals
63
Size
49
Momentum
46
Volatility
37
Revisions
29

Growth (96): Sales and profits are climbing, and climbing faster than before.

Revisions (29): Analysts have, on balance, been cutting their forecasts.

The rank is the raw material. Whether the rules would actually own Phathom Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

PHAT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHAT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26PHATHigh $29Median $24Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $13Median $24High $29

The green dot is the last close — the median target sits +167.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 July 2026GuggenheimMaintainsBuy$25 → $22
31 July 2026HC Wainwright & Co.ReiteratesBuy$26
30 July 2026NeedhamMaintainsBuy$28 → $22
17 June 2026HC Wainwright & Co.ReiteratesBuy—
17 June 2026HC Wainwright & Co.ReiteratesBuy$26
27 Mar 2026BarclaysUpgradeOverweight—
27 Feb 2026GuggenheimMaintainsBuy—
9 Dec 2025BarclaysInitiatesEqual-Weight—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
9 June 2025Craig-HallumMaintainsBuy—
9 June 2025HC Wainwright & Co.ReiteratesBuy—
6 June 2025NeedhamMaintainsBuy—
2 May 2025Craig-HallumMaintainsBuy—
2 May 2025Goldman SachsMaintainsNeutral—
2 May 2025GuggenheimMaintainsBuy—
2 May 2025HC Wainwright & Co.MaintainsBuy—
21 Apr 2025NeedhamReiteratesBuy—
17 Apr 2025Goldman SachsMaintainsNeutral—
9 Apr 2025NeedhamReiteratesBuy—
2 Apr 2025GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PHAT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Phathom Pharmaceuticals, Inc. (PHAT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
3.0×

Cheaper than 42% of US stocks

Price / book
−2.2×

Cheaper than 95% of US stocks

EV / EBITDA
−26.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
88.0%

Higher than 92% of US stocks

Earnings growth (YoY)
88.0%

Higher than 85% of US stocks

Gross margin
79.7%

Higher than 91% of US stocks

Operating margin
−5.3%

Higher than 29% of US stocks

Net margin
−41.3%

Higher than 11% of US stocks

Returns & dividend
Return on equity
50.5%

Higher than 93% of US stocks

Return on assets
−8.8%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PHAT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHATPhathom Pharmaceuticals, Inc.$697.9M
76
CLYMClimb Bio, Inc.$681.4M
72
RIGLRigel Pharmaceuticals, Inc.$681.1M
85
NVCTNuvectis Pharma, Inc.$678.4M
72
CTMXCytomX Therapeutics, Inc.$670.1M
56
FTHFaeth Therapeutics, Inc.$702.2M
56
XOMAXOMA Royalty Corp.$705.1M
—
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHAT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest PHAT news & analysis

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

Business Wire · 3 Aug 2026negative

Phathom Pharmaceuticals lowered its full-year 2026 revenue guidance to $310 million–$325 million from a prior range of $320 million–$345 million, falling below Wall Street consensus estimates of about $332 million. Following the news, Levi & Korsinsky notified investors of an investigation into the company and encouraged shareholders who suffered losses to come forward.

Why it matters — PHAT watchers would care because the guidance cut and the resulting investor investigation raise questions about the company's outlook and its disclosures.

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

Phathom Pharmaceuticals held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covers the company's financial results and business developments for the quarter.

Why it matters — Earnings call transcripts provide investors and analysts with direct insight into management's discussion of quarterly performance and forward-looking outlook.

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

PRNewsWire · 30 July 2026negative

Levi & Korsinsky notified investors of a pending investigation into Phathom Pharmaceuticals after the company lowered its FY 2026 revenue guidance from a high of $345 million to a revised outlook topping out at $325 million, despite building a sales force of more than 290 representatives.

Why it matters — Shareholders absorbed a revenue guidance decline of up to $20 million, and an investigation has been announced regarding the company's outlook.

Phathom Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 30 July 2026positive

Phathom Pharmaceuticals reported 88% year-over-year revenue growth in the second quarter of 2026 and achieved positive operating profit excluding stock-based compensation for the first time, reaching the milestone one quarter earlier than planned.

Why it matters — The early achievement of positive operating profit (excluding stock-based compensation) signals improving financial discipline and could shorten the company's path to full profitability.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Zacks Investment Research · 30 July 2026positive

Phathom Pharmaceuticals reported break-even quarterly earnings per share for Q2, beating the Zacks Consensus Estimate of a loss of $0.06 per share and improving from a loss of $0.79 per share a year ago.

Why it matters — This marks a significant earnings improvement for PHAT, as the company achieved break-even results when analysts had expected a loss.

FAQ

Frequently asked questions about PHAT stock

What is the PHAT stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Phathom Pharmaceuticals, Inc. have a median 12-month price target of $24, with estimates ranging from $13 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHAT stock a buy right now?

Of the 11 analysts covering Phathom Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phathom Pharmaceuticals, Inc. 76 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHAT?

As at 1 Aug 2026, Phathom Pharmaceuticals, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will PHAT stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +167.3% from the last close, and Ticker Nerd's factor model ranks Phathom Pharmaceuticals, Inc. 76 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHAT stock forecast for 2030?

No analyst covering Phathom Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $29 over the next 12 months.

How has PHAT stock performed over the past year?

Phathom Pharmaceuticals, Inc. returned +7.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phathom Pharmaceuticals, Inc. do?

Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid.

What is the latest news on PHAT?

The most recent item we track (Business Wire, 3 Aug 2026): "PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)". Phathom Pharmaceuticals lowered its full-year 2026 revenue guidance to $310 million–$325 million from a prior range of $320 million–$345 million, falling below Wall Street consensus estimates of about $332 million. Following the news, Levi & Korsinsky notified investors of an investigation into the company and encouraged shareholders who suffered losses to come forward.

Company

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid. Its flagship product, VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, is approved for adults with erosive gastroesophageal reflux disease (GERD) and heartburn, as well as non-erosive GERD. The company also offers VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for treating Helicobacter pylori infections. These products address key unmet needs in the GI sector by providing superior acid suppression compared to traditional proton pump inhibitors. Phathom Pharmaceuticals Inc. emphasizes commercializing these therapies in the United States, supported by ongoing clinical data presentations at medical conferences and prescription growth tracking. Founded in 2018 and headquartered in Florham Park, New Jersey, the company plays a significant role in advancing innovative GI treatments within the biopharmaceutical market.

CEO Mr. Steven L. Basta M.B.A. · 371 employees · United States · https://www.phathompharma.com